EA201590061A1 - Фармацевтическая композиция - Google Patents

Фармацевтическая композиция

Info

Publication number
EA201590061A1
EA201590061A1 EA201590061A EA201590061A EA201590061A1 EA 201590061 A1 EA201590061 A1 EA 201590061A1 EA 201590061 A EA201590061 A EA 201590061A EA 201590061 A EA201590061 A EA 201590061A EA 201590061 A1 EA201590061 A1 EA 201590061A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
antibody
high concentration
present
viscosity
Prior art date
Application number
EA201590061A
Other languages
English (en)
Inventor
Эндрю Джеффри Йэйтс
Джеймс Грегори Клипстоун
Original Assignee
Юсб Фарма С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745904&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201590061(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юсб Фарма С.А. filed Critical Юсб Фарма С.А.
Publication of EA201590061A1 publication Critical patent/EA201590061A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к способам и к средствам для уменьшения вязкости фармацевтической композиции, содержащей антитело или другой терапевтический белок в высокой концентрации. В настоящем изобретении предлагается жидкая фармацевтическая композиция, содержащая антитело в высокой концентрации с уменьшенной вязкостью, которая не препятствует процессированию или инъекции фармацевтической композиции.
EA201590061A 2012-06-21 2013-06-20 Фармацевтическая композиция EA201590061A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261662621P 2012-06-21 2012-06-21
PCT/EP2013/062898 WO2013190047A1 (en) 2012-06-21 2013-06-20 Pharmaceutical formulation

Publications (1)

Publication Number Publication Date
EA201590061A1 true EA201590061A1 (ru) 2015-05-29

Family

ID=48745904

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590061A EA201590061A1 (ru) 2012-06-21 2013-06-20 Фармацевтическая композиция

Country Status (25)

Country Link
US (1) US20150150979A1 (ru)
EP (1) EP2864356A1 (ru)
JP (1) JP6157611B2 (ru)
KR (1) KR20150032941A (ru)
CN (1) CN104520326A (ru)
AR (1) AR091530A1 (ru)
AU (1) AU2013279347A1 (ru)
BR (1) BR112014031841A2 (ru)
CA (1) CA2876012A1 (ru)
CL (1) CL2014003283A1 (ru)
CO (1) CO7170174A2 (ru)
EA (1) EA201590061A1 (ru)
EC (1) ECSP15002095A (ru)
HK (1) HK1205146A1 (ru)
IL (1) IL235921A0 (ru)
MA (1) MA37777B1 (ru)
MX (1) MX2014014717A (ru)
NZ (1) NZ702342A (ru)
PE (1) PE20150190A1 (ru)
PH (1) PH12014502596A1 (ru)
SG (1) SG11201407779YA (ru)
TN (1) TN2014000498A1 (ru)
TW (1) TW201406398A (ru)
WO (1) WO2013190047A1 (ru)
ZA (1) ZA201409020B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038811A2 (en) 2013-09-11 2015-03-19 Arsia Therapeutics, Inc. Liquid protein formulations containing ionic liquids
JP6716577B2 (ja) 2014-10-01 2020-07-01 イーグル・バイオロジクス・インコーポレイテッドＥａｇｌｅ Ｂｉｏｌｏｇｉｃｓ， Ｉｎｃ． 粘度低下物質を含有する、多糖および核酸の調合薬
KR102293156B1 (ko) 2016-05-28 2021-08-24 라지브 간디 센트레 포 바이오테크놀로지, 언 오토노모우스 인스티튜트 언더 더 디파트먼트 오브 바이오-테크놀로지, 거버먼트 오브 인디아 간세포 암종에 대한 치료제로서의 우트트로시드(Uttroside) B 및 이의 유도체
JP2019536761A (ja) * 2016-10-31 2019-12-19 フレゼニウス カービ ドイチュラント ゲーエムベーハー 液体医薬組成物
US10980881B2 (en) 2017-01-11 2021-04-20 Celltrion Inc. Stable liquid formula having an anti-TNFalpha antibody, acetate buffer and glycine
EP3624846A1 (en) 2017-05-16 2020-03-25 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
EP4247386A1 (en) * 2020-11-18 2023-09-27 Bexson Biomedical, Inc. Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
US8658773B2 (en) * 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
ZA200507757B (en) * 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
CA2600608A1 (en) * 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Composition comprising human igg2 antibody and chelating agent
AU2008204901A1 (en) * 2007-01-09 2008-07-17 Wyeth Anti-IL-13 antibody formulations and uses thereof
AU2008266051B2 (en) * 2007-06-14 2014-07-31 Biogen Ma Inc. Antibody formulations
MX2012012743A (es) * 2010-05-03 2012-11-23 Genentech Inc Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
KR101861867B1 (ko) * 2010-05-14 2018-05-29 암젠 인크 고농도의 항체 제제
WO2012003470A2 (en) * 2010-07-02 2012-01-05 Medimmune, Llc Antibody formulations
EP2694708A4 (en) * 2011-04-07 2014-10-01 Glaxosmithkline Llc FORMULATIONS WITH REDUCED VISCOSITY

Also Published As

Publication number Publication date
TN2014000498A1 (en) 2016-03-30
MA20150436A1 (fr) 2015-11-30
JP2015520206A (ja) 2015-07-16
SG11201407779YA (en) 2015-02-27
AU2013279347A1 (en) 2014-12-18
CO7170174A2 (es) 2015-01-28
WO2013190047A1 (en) 2013-12-27
PE20150190A1 (es) 2015-02-13
JP6157611B2 (ja) 2017-07-05
NZ702342A (en) 2016-07-29
MA37777B1 (fr) 2017-07-31
ECSP15002095A (es) 2015-11-30
PH12014502596A1 (en) 2015-01-12
EP2864356A1 (en) 2015-04-29
BR112014031841A2 (pt) 2017-06-27
IL235921A0 (en) 2015-01-29
CL2014003283A1 (es) 2016-04-01
CA2876012A1 (en) 2013-12-27
US20150150979A1 (en) 2015-06-04
ZA201409020B (en) 2016-09-28
HK1205146A1 (en) 2015-12-11
KR20150032941A (ko) 2015-03-31
TW201406398A (zh) 2014-02-16
AR091530A1 (es) 2015-02-11
CN104520326A (zh) 2015-04-15
MX2014014717A (es) 2015-03-06

Similar Documents

Publication Publication Date Title
EA201590061A1 (ru) Фармацевтическая композиция
EA201590388A1 (ru) Способы лечения таупатии
MX2021008816A (es) Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, anticuerpos de union a interleucina 8 (il-8) y usos de los mismos.
EA201890278A1 (ru) Антитела к pd-l1
EA201592203A1 (ru) Способы лечения таупатии
MX2021005907A (es) Formulaciones de proteinas liquidas que contienen liquidos ionicos.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
EA201492101A1 (ru) Антитела против fcrn
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
EA201592105A1 (ru) Толерогенные синтетические наноносители и терапевтические макромолекулы для снижения или усиления фармакодинамических эффектов
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
MX360368B (es) Regiones de anticuerpo modificado y sus usos.
EA201892509A1 (ru) Антитела к гемагглютинину и способы применения
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
EA201401065A1 (ru) Ang2-связывающие молекулы
EA201300133A1 (ru) Фармацевтическая композиция и способ лечения ожирения, сопутствующих метаболических расстройств и зависимости от психоактивных веществ
UA117228C2 (uk) Фармацевтична композиція, що містить антитіло до gm-csf
EA201690992A1 (ru) Антитела, специфичные к fcrn
EA201491702A1 (ru) Оптимизированные терапевтические агенты для подкожного введения
EA201792608A2 (ru) Применение белков p3 бактериофага в качестве агентов, связывающих амилоид
EA201301090A1 (ru) Антидоты антикоагулянтов
TW201613981A (en) Compositions and methods for the diagnosis of rheumatoid arthritis
BR112015031585A2 (pt) composição farmacêutica
TN2013000068A1 (en) Anti-vegfr-3 antibody compositions